HALO - Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road
San Diego, CA 92121
United States
858-794-8889
http://www.halozyme.com

Sektor: Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 281

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Helen I. Torley	Pres, CEO & Director	1,57M	N/A	1963
Ms. Laurie D. Stelzer	Sr. VP & CFO	802,9k	N/A	1968
Mr. Harry J. Leonhardt	Sr. VP, Gen. Counsel & Corp. Sec.	757,57k	N/A	1957
Dr. Dimitrios Chondros	Chief Medical Officer & Sr. VP	937,77k	N/A	1965
Mr. Benjamin J. Hickey	Sr. VP & Chief Commercial Officer	828,89k	N/A	1975

Die Beträge haben den Stand 31. Dezember 2018 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Halozyme Therapeutics, Inc., a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit. The company's products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its pipeline include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to enhance resorption of radiopaque agents. The company also develops PEGPH20, a therapy that is in Phase III clinical trial for pancreatic ductal adenocarcinoma; in Phase Ib clinical trial for non-small cell lung cancer; in Phase Ib/II clinical trial for patients with previously treated metastatic pancreatic ductal adenocarcinoma; in Phase Ib/II clinical trial for patients with gastric cancer; and in Phase Ib/II for cholangiocarcinoma and gall bladder cancer. It has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. The company was founded in 1998 and is headquartered in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.s ISS Governance QualityScore, Stand 29. Juli 2019, lautet 3. Die grundlegenden Scores sind Audit: 2, Vorstand: 1, Shareholderrechte: 5, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.